Gabapentin Tablet, Film Coated
Product Images NDC 71335-1132

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustrated pharmacokinetic formula calculating creatinine clearance (CLCr) based on age, weight, serum creatinine level, and a factor adjusting for female patients.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of gabapentin showing a cyclohexane ring bonded to an amino group (CH2NH2) and an acetic acid group (CH2CO2H).*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph comparing mean pain scores over an 8-week period between placebo and Gabapentin 3600 mg/day, showing a 4-week dose titration period followed by a 4-week fixed dose period. The graph depicts decreasing pain scores for the Gabapentin group and relatively stable scores for the placebo group across weeks.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period, while the y-axis indicates mean pain scores ranging from 0 to 10. Gabapentin groups show a greater reduction in pain scores compared to placebo over time.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar graph showing the proportion of responders with at least 50% reduction in pain score at endpoint in controlled postherpetic neuralgia (PHN) studies. Two studies are compared with different treatments: placebo (PBO), Gabapentin (GBP) 1800 mg, GBP 2400 mg, and GBP 3600 mg. Statistical significance is indicated for the Gabapentin groups versus placebo.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing the percent difference versus daily dose in mg for Gabapentin in three studies labeled a, b, and c. The x-axis shows daily doses ranging from 600 to 1800 mg, and the y-axis shows the percent difference up to 22%. Data points for each study are represented by distinct markers and show variation in difference percentages across doses.*

FDA Label Image

Label (Lbl713351132)

Gabapentin 600 mg tablet label from Bryant Ranch Prepack, displaying storage instructions (20°-25°C), warnings about dizziness, and advising to keep drugs out of children's reach. The label includes a comparison reference to Neurontin 600 mg tablets by Vivimed Life Sciences Pvt Ltd, lot number 1523487, a quantity of 30 tablets, and the NDC number 71335-11321.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.